Published in Invest New Drugs on December 18, 2009
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res (2012) 1.06
MAPK/ERK Signaling in Osteosarcomas, Ewing Sarcomas and Chondrosarcomas: Therapeutic Implications and Future Directions. Sarcoma (2012) 0.93
Cryoimmunology for malignant bone and soft-tissue tumors. Int J Clin Oncol (2011) 0.91
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. BMC Cancer (2013) 0.90
New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol (2012) 0.89
A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma. Sarcoma (2016) 0.84
The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep (2014) 0.83
Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. Clin Sarcoma Res (2014) 0.80
Targeted therapies in sarcomas: challenging the challenge. Sarcoma (2012) 0.80
Targeted polytherapy in small cell sarcoma and its association with doxorubicin. Mol Oncol (2014) 0.80
Targeted therapy in sarcomas other than GIST tumors. J Surg Oncol (2014) 0.78
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer (2015) 0.76
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study. Invest New Drugs (2013) 0.75
Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma. Sarcoma (2016) 0.75
Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol (2016) 0.75
Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Reporting results of cancer treatment. Cancer (1981) 28.83
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
BAY 43-9006: preclinical data. Curr Pharm Des (2002) 1.76
Should patients with advanced sarcomas be treated with chemotherapy? . Eur J Cancer (1998) 1.42
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res (2004) 1.19
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2000) 1.08
Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol (2006) 0.98
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res (2007) 0.94
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer (1998) 0.93
C-kit, GIST, and imatinib. Recent Results Cancer Res (2007) 0.93
Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. Curr Oncol Rep (2007) 0.88
[Epidemiology of soft tissue sarcomas in adults]. Presse Med (2001) 0.83
Targeted therapies for soft-tissue sarcomas. Expert Rev Anticancer Ther (2007) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst (2007) 5.13
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol (2002) 3.53
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol (2002) 3.25
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13
Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer (2006) 3.06
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet (2011) 2.68
Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol (2000) 2.67
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol (2006) 2.48
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 2.23
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res (2007) 2.20
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol (2004) 2.13
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10
BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol (2011) 2.10
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol (2006) 2.06
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (1996) 2.06
Intensive treatment of multiple myeloma and criteria for complete remission. Lancet (1989) 2.04
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res (2011) 2.03
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. Clin Colorectal Cancer (2002) 2.02
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res (1991) 1.94
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol (2008) 1.91
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol (2003) 1.88
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2006) 1.84
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82